Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig® Publisert: 04.08.2022 Navamedic ASA acquires Impolin AB and bolsters its product portfolio Publisert: 05.05.2022 Navamedic ASA launches SmectaGO[®] – an innovative on-the-go product for treatment of diarrhea Publisert: 16.02.2022 Treating the side-effects of the pandemic Publisert: 24.06.2021 Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has won the tender for certain antibiotics to the Norwegian hospital market Publisert: 17.06.2021 Navamedic ASA: Icepharma new distributor of antibiotics to the Icelandic market Publisert: 07.05.2021 FørsteForrige12345NesteSiste
Navamedic ASA – Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig® Publisert: 04.08.2022
Navamedic ASA launches SmectaGO[®] – an innovative on-the-go product for treatment of diarrhea Publisert: 16.02.2022
Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has won the tender for certain antibiotics to the Norwegian hospital market Publisert: 17.06.2021
Navamedic ASA: Icepharma new distributor of antibiotics to the Icelandic market Publisert: 07.05.2021